Pharmacometric analyses help make assessments involving multiple benefits and risks of a drug. See here how the relationship between tepotinib exposure, and efficacy and safety outcomes (including QTcF) provided important quantitative pharmacologic support regarding the 500 mg/day dosage. Tepotinib is a highly selective MET inhibitor approved for the treatment of non-small cell lung cancer harboring METex14 skipping alterations.
Find the publication here: Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations
Pharmetheus affiliates: Sofia Friberg Hietala and@Joakim Nyberg, with support from Enrica Mezzalana, Giovanni Smania, Richard Anziano, Niclas Jonsson, Eric Sandström and Peteris Prusis. QC by Arnaud Gaby, Kim Nijs and Monique Wouters
